SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: dougle who wrote (102)12/1/1997 5:16:00 PM
From: MarcG  Respond to of 857
 
Doug, For information on how the CFS trail is going according to a relative of one of its patients, please refer to message # 20 on the Yahoo boards for HEB. I don't think it would be appropriate for the company to comment on the trials until the 6 month period has expired, sometime in Jan-Feb. Renewing administration of Ampligen for the same patient requires FDA approval. It may even be possible to see news regarding other trials (AIDS, Hepatitis) or diagnostics
(Diagen) before CFS news.



To: dougle who wrote (102)12/2/1997 9:10:00 AM
From: Graham Marshman  Read Replies (1) | Respond to of 857
 
dougle,
Yes, this is a little strange, especially when you consider how close Westergaard is to HEB. Why announce that they're going to be conferring with the management. It certainly could be taken as negative - the alternative is the setup where they return in a week having "conferred" with positive responses to all the questions.

Graham


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News